Seminars in ophthalmology · 2025
Comparative Outcomes of Teprotumumab and Tocilizumab in Thyroid Eye Disease: The First Retrospective Study from the United Arab Emirates and Gulf Region of the Middle East.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eatamadi Habibullah
Аннотация
METHODS: A retrospective analysis of 44 TED patients (22 teprotumumab, 2023-2025 at Sheikh Shakhbout Medical City and 22 tocilizumab, 2018-2024 at Sheikh Khalifa Medical City) was conducted. Outcomes included proptosis reduction (Hertel exophthalmometry), clinical activity score (CAS) improvement, diplopia improvement, quality of life (QoL) improvement (TED-QOL), recurrence rates, and adverse events. Mann-Whitney U tests and chi-square/Fisher's exact tests were used (p < .05).
RESULTS: Teprotumumab produced greater mean proptosis reduction (2.55 ± 1.01 mm vs 2.07 ± 1.07 mm, p = .04) and a larger mean CAS improvement (5.18 ± 1.99 vs 4.59 ± 1.82, p = .34). Diplopia improvement occurred in 78.6% vs 75.0% of patients (p = .82), while ≥1-grade improvement by Gorman criteria was achieved in 59.1% of each group (p = .61). Quality-of-life improvement averaged 4.2 ± 1.4 vs 3.4 ± 1.5 points (p = .18). Disease recurrence was lower with teprotumumab (4.5% vs 13.6%, p = .28). Adverse events occurred in 54.5% (teprotumumab) and 43.5% (tocilizumab) patients (p = .47), and were generally mild and reversible.
CONCLUSION: Teprotumumab and tocilizumab improved TED outcomes, with teprotumumab showing trends toward better proptosis reduction and lower recurrence. Larger studies are needed to confirm these findings.
RESULTS: Teprotumumab produced greater mean proptosis reduction (2.55 ± 1.01 mm vs 2.07 ± 1.07 mm, p = .04) and a larger mean CAS improvement (5.18 ± 1.99 vs 4.59 ± 1.82, p = .34). Diplopia improvement occurred in 78.6% vs 75.0% of patients (p = .82), while ≥1-grade improvement by Gorman criteria was achieved in 59.1% of each group (p = .61). Quality-of-life improvement averaged 4.2 ± 1.4 vs 3.4 ± 1.5 points (p = .18). Disease recurrence was lower with teprotumumab (4.5% vs 13.6%, p = .28). Adverse events occurred in 54.5% (teprotumumab) and 43.5% (tocilizumab) patients (p = .47), and were generally mild and reversible.
CONCLUSION: Teprotumumab and tocilizumab improved TED outcomes, with teprotumumab showing trends toward better proptosis reduction and lower recurrence. Larger studies are needed to confirm these findings.